https://parkinson.everpharma.com/terapias-avanzadas-y-seguimiento-remoto-a-pacientes-barcelona-29-de-junio-2020-eduardo-tolosa-catedratico-de-neurologia-universidad-de-barcelona/2023-04-21T14:43:58+02:00https://parkinson.everpharma.com/clinical-considerations-in-selection-between-non-oral-continuous-drug-delivery-cdd-and-deep-brain-stimulation-dbs-prof-dr-andres-ceballos-baumann-parkinson-fachklinik-schon-klinik-munchen/2023-04-21T14:45:05+02:00https://parkinson.everpharma.com/continuous-dopaminergic-treatment-impact-of-routes-of-administration-jean-christophe-corvol-cic-neurosciences-hopital-pitie-salpetriere/2023-04-21T14:46:02+02:00https://parkinson.everpharma.com/m-otor-and-non-motor-aspects-of-early-morning-off-tove-henriksen-md-movement-disorder-clinic-university-hospital-of-copenhagen-nymphaea-caerula-blue-egyptian-water-lily-royal-botanic-gardens-kew/2023-04-21T14:46:42+02:00https://parkinson.everpharma.com/prof-fabrizio-stocchi-department-of-neurology-university-and-institute-for-research-and-medical-care-irccs-san-raffaele-rome-italy/2023-04-21T14:47:10+02:00https://parkinson.everpharma.com/how-to-support-pa%ef%bf%bdent-s-adherence-to-device-aided-advanced-therapies-therapeutic-strategies-in-advanced-parkinson-s-disease-wien-2018-eduardo-tolosa-professor-of-neurology-uni/2023-04-21T14:47:40+02:00https://parkinson.everpharma.com/unmet-needs-in-advanced-pd-dieter-volc-therapeutic-strategies-in-advanced-parkinsons-disease-with-focus-on-infusion-therapy-december-1-st-2018-wien/2023-04-21T14:48:03+02:00https://parkinson.everpharma.com/neuropsychiatric-side-effects-of-apomorphine-in-parkinsons-disease-patients-prof-teus-van-laar-director-parkinson-expertise-center-university-medical-center-groningen-the-netherlands/2023-04-21T14:51:28+02:00https://parkinson.everpharma.com/levodopa-induced-motor-complications-in-pd-clinical-presentation-and-underlying-mechanisms-werner-poewe-dept-of-neurology-medical-university-innsbruck-austria-4th-scientific-symposium-moto/2023-04-21T14:51:52+02:00https://parkinson.everpharma.com/supporting-patients-with-pathways-and-pitfalls-during-a-pandemic-lessons-learned-jane-price-parkinsons-nurse-advanced-practitioner-msc-bsc-nmp-rgn-powys-teaching-health-board/2023-04-21T14:50:17+02:00https://parkinson.everpharma.com/new-treatments-for-motor-and-non-motor-complications-in-parkinsons-disease-pr-olivier-rascol-clinical-investigation-center-cic1436-department-of-clinical-pharmacology-department-of-neuros/2026-02-17T10:40:52+01:00https://parkinson.everpharma.com/justus-liebig-universitat-giesen-neurologische-klinik-dbs-and-apomorphine-iris-reuter/2023-04-21T14:51:08+02:00https://parkinson.everpharma.com/effect-of-device-aided-therapies-on-quality-of-life-qol-in-advanced-pd-prof-dr-med-l-tonges-4th-scientific-symposium-on-parkinson-s-disease-symptom-management-vienna-oct-15/2023-04-21T14:49:50+02:00https://parkinson.everpharma.com/selecting-dbs-or-infusion-therapy-patients-in-advanced-pd-and-5-year-follow-up-angelo-antonini-parkinson-and-movement-disorders-unit-department-of-neuroscience-university-of-padua/2023-04-21T14:52:58+02:00https://parkinson.everpharma.com/quality-of-life-in-parkinsonss-disease-improved-by-apomorphine-pump-prof-david-devos-medical-pharmacology-neurology-lille-university-university-hospital-center-inserm-u1171-france/2023-04-21T14:53:24+02:00https://parkinson.everpharma.com/garcia-ruiz_symp_251117/2023-04-21T14:53:49+02:00https://parkinson.everpharma.com/per-odin-professor-department-of-neurology-lund-university-sweden-chairman-department-of-neurology-central-hospital-bremerhaven-germany-subcutaneous-apomorphine-injections/2023-04-21T14:54:14+02:00https://parkinson.everpharma.com/financial-disclosures-honoraria-for-speaking-engagements-by-abbvie-desitin-grunenthal-licher-m-t-medtronic-orion-pharma-ucb-and-zambon-travel-costs-were-supported-by-l/2023-04-21T14:54:42+02:00https://parkinson.everpharma.com/long-term-aspects-of-oral-dopamine-agonists-and-s-c-apomorphine-dieter-volc-therapeutic-strategies-in-advanced-parkinsons-disease-with-focus-on-infusion-therapy-november-25-th-2017-wien/2023-04-21T14:56:09+02:00https://parkinson.everpharma.com/auffret_symp_301119/2023-04-21T14:57:02+02:00https://parkinson.everpharma.com/non-motor-parkinsons-disease-and-advanced-therapies-k-ray-chaudhuri-parkinsons-foundation-centre-of-excellence-at-king-s-college-hospital-and-kings-college-london/2023-04-21T14:57:34+02:00https://parkinson.everpharma.com/living-with-advanced-pd-remembering-who-lives-with-pd-early-symptoms-progressions-impacts-disease-or-iatrogenic-a-patients-voice-su/2023-04-21T14:57:58+02:00https://parkinson.everpharma.com/vienna-30-11-2019-therapeutic-strategies-of-device-aided-therapies-in-advanced-pd-wolfgang-jost-parkinson-klinik-ortenau-universitatsklinik-freiburg/2023-04-21T14:58:26+02:00https://parkinson.everpharma.com/ever-pharma-scientific-symposium-vienna-november-30th-2019-regina-katzenschlager-head-department-of-neurology-and-karl-landsteiner-institute-for-neuroimmunological-and-neurodegenerative-disorders/2023-04-21T14:58:48+02:00https://parkinson.everpharma.com/hannah-martin-parkinsons-disease-nurse-specialist-pdns-msc-a-c-p-bsc-rgn-ip/2023-04-21T14:59:50+02:00https://parkinson.everpharma.com/apomorphine-infusion-pump-therapy-k-seppi-universitatsklinik-fur-neurologie-medizinische-universitat-innsbruck-klaus-seppitirol-kliniken-at-scientific-cme-webinar-device-assisted-therapies-in-p/2023-04-21T15:03:55+02:00https://parkinson.everpharma.com/apomorphine-and-deep-brain-stimulation-a-ngel-sesar-md-phd-movement-disorder-unit-coordinator-department-of-neurology-hospital-clinico-universitario-santiago-de-compostela-spain-1/2023-04-21T15:03:10+02:00https://parkinson.everpharma.com/apomorphine-s-c-injection-therapy-a-powerful-tool-for-managing-parkinsons-disease-friederike-sixel-doring-paracelsus-elena-klinik-kassel-germany-friederike-sixelpkd-de/2023-04-21T15:03:29+02:00https://parkinson.everpharma.com/developing-consensus-among-movement-disorder-specialists-on-clinical-indicators-for-identification-and-management-of-advanced-parkinsons-disease-a-multi-country-delphi-panel-approach/2023-11-29T11:11:34+01:00https://parkinson.everpharma.com/apomorphine-subcutaneous-infusion-in-patients-with-parkinsons-disease-with-persistent-motor-fluctuations-toledo/2023-11-29T11:11:11+01:00https://parkinson.everpharma.com/long-term-safety-and-efficacy-of-apomorphine-infusion-in-pd-patients-with-persistent-motor-fluctuations-toledo-open-label-phase/2023-11-29T11:08:36+01:00https://parkinson.everpharma.com/apomorphine-subcutaneous-injection-for-the-management-of-morning-akinesia-in-parkinsons-disease/2024-02-21T14:48:17+01:00https://parkinson.everpharma.com/comparison-of-subcutaneous-apomorphine-versus-dispersible-madopar-latency-and-effect-duration-in-parkinsons-disease-patients/2024-02-21T14:48:37+01:00https://parkinson.everpharma.com/waiting-for-on-a-major-problem-in-patients-with-parkinson-disease-and-on-off-motor-fluctuations/2024-02-21T14:48:02+01:00https://parkinson.everpharma.com/on-demand-therapy-for-off-episodes-in-parkinsons-disease/2024-02-21T14:47:39+01:00https://parkinson.everpharma.com/apomorphine-infusions-in-advanced-parkinson-disease/2024-02-21T14:50:54+01:00https://parkinson.everpharma.com/should-on-demand-treatments-for-parkinsons-disease-off-episodes-be-used-earlier/2024-02-21T14:50:36+01:00https://parkinson.everpharma.com/quality-of-life-in-parkinsons-disease-improved-by-apomorphine-pump-the-optipump-cohort-study/2023-06-20T15:44:34+02:00https://parkinson.everpharma.com/parkinsons-disease-introduction/2025-08-14T12:43:31+02:00https://parkinson.everpharma.com/non-motor-symptoms-in-parkinsons-disease-eye-nose-mouth/2025-08-14T12:49:27+02:00https://parkinson.everpharma.com/non-motor-symptoms-in-parkinsons-disease-gastrointestinal-symptoms/2025-08-14T12:49:44+02:00https://parkinson.everpharma.com/diagnostic-of-parkinsons-disease/2025-08-22T11:48:03+02:00https://parkinson.everpharma.com/risk-protective-factors-of-parkinsons-disease/2025-08-14T12:50:17+02:00https://parkinson.everpharma.com/classification-of-parkinsons-disease-an-overview/2025-08-14T12:45:19+02:00https://parkinson.everpharma.com/classification-of-parkinsons-plus-syndromes-msa-psp-cbd/2025-09-18T14:18:31+02:00https://parkinson.everpharma.com/cardinal-symptoms-in-parkinsons-disease/2025-08-14T12:46:10+02:00https://parkinson.everpharma.com/incidence-prevalence-parkinsons-disease/2025-08-14T12:46:26+02:00https://parkinson.everpharma.com/parkinsons-disease-and-the-role-of-neurotransmitters/2025-08-14T12:47:00+02:00https://parkinson.everpharma.com/motor-symptoms-in-parkinsons-disease/2025-08-14T12:47:29+02:00https://parkinson.everpharma.com/non-motor-symptoms-in-parkinsons-disease-automatic-symptoms/2025-08-22T12:31:59+02:00https://parkinson.everpharma.com/non-motor-symptoms-in-parkinsons-disease-brain/2026-07-30T15:43:46+02:00https://parkinson.everpharma.com/treatment-options-for-parkinsons-disease-an-overview/2025-08-13T14:45:47+02:00https://parkinson.everpharma.com/treatment-options-for-parkinsons-disease-levodopa/2025-08-26T13:11:37+02:00https://parkinson.everpharma.com/treatment-options-of-parkinsons-disease-comt-inhibitor/2025-10-29T15:17:25+01:00https://parkinson.everpharma.com/treatment-options-of-parkinsons-disease-mao-b-inhibitors/2025-08-26T13:14:23+02:00https://parkinson.everpharma.com/treatment-options-of-parkinsons-disease-dopamine-agonists/2026-07-31T13:07:35+02:00https://parkinson.everpharma.com/treatment-options-for-parkinsons-disease-ach-inhibitors-nmda-glutamate-receptor-adenosin-a-2a-antagonists-anticholinergics-cannabinoids/2025-08-13T14:49:40+02:00https://parkinson.everpharma.com/non-drug-treatment-in-parkinsons-disease/2025-08-13T14:55:44+02:00https://parkinson.everpharma.com/treatment-options-for-parkinsons-disease-deep-brain-stimulation-dbs/2025-08-14T08:19:49+02:00https://parkinson.everpharma.com/apomorphine/2026-08-12T13:09:11+02:00https://parkinson.everpharma.com/side-effects-of-apomorphine-s-c/2025-08-14T09:02:00+02:00https://parkinson.everpharma.com/pre-treatment-with-domperidon/2025-08-26T13:30:17+02:00https://parkinson.everpharma.com/panel-discussion-symposium-2022__trashed/2023-06-21T10:23:01+02:00https://parkinson.everpharma.com/apomorphine-monotherapy-in-the-treatment-of-refractory-motor-complicationsof-parkinsons-disease-long-term-follow-up-study-of-64-patients/2024-02-21T14:51:42+01:00https://parkinson.everpharma.com/euroinf-2-subthalamic-stimulation-apomorphine-and-levodopa-infusion-in-parkinsons-disease/2024-02-21T14:52:26+01:00https://parkinson.everpharma.com/apomorphine-pharmacological-properties/2024-02-21T14:53:07+01:00https://parkinson.everpharma.com/the-goal-of-the-continuous-apomorphine-pump-treatment/2023-07-24T15:19:56+02:00https://parkinson.everpharma.com/patient-selection-for-the-continuous-pump-treatment-medical-aspects/2023-07-24T15:20:36+02:00https://parkinson.everpharma.com/part-1-factors-influencing-the-success-of-continuous-apomorphine-pump-treatment/2023-07-24T15:21:37+02:00https://parkinson.everpharma.com/part-2-factors-influencing-the-success-of-continuous-apomorphine-pump-treatment/2023-07-24T15:22:07+02:00https://parkinson.everpharma.com/part-3-factors-influencing-the-success-of-continuous-apomorphine-pump-treatment/2023-07-24T15:22:35+02:00https://parkinson.everpharma.com/specific-areas-of-application-for-continuous-apomorphine-pump-treatment/2023-07-31T08:04:06+02:00https://parkinson.everpharma.com/basic-tips-for-continuous-apomorphine-pump-initiation/2025-08-13T14:06:30+02:00https://parkinson.everpharma.com/the-4-titration-phases-of-apomorphine-pump-treatment/2025-08-26T13:31:14+02:00https://parkinson.everpharma.com/outpatient-initiation-of-continuous-apomorphine-pump-treatment/2025-08-13T14:12:40+02:00https://parkinson.everpharma.com/how-to-titrate-continuous-apomorphine-pump-treatment-with-previous-dopamine-agnonists/2025-08-13T14:15:02+02:00https://parkinson.everpharma.com/avoiding-polypharmacy-in-parkinsons-medication/2025-08-13T14:16:18+02:00https://parkinson.everpharma.com/avoiding-certain-drug-groups-in-parkinsons/2025-08-13T14:18:08+02:00https://parkinson.everpharma.com/part-1-the-nursing-service-at-the-hospital/2025-08-13T14:19:45+02:00https://parkinson.everpharma.com/part-2-the-nursing-service-after-discharge-from-hospital/2023-07-24T15:26:10+02:00https://parkinson.everpharma.com/patient-selection-for-intermittend-apomorphine-pen-therapy/2023-08-25T12:07:40+02:00https://parkinson.everpharma.com/special-areas-for-intermittend-apomorphine-pen-therapy/2023-08-25T12:00:32+02:00https://parkinson.everpharma.com/general-information-and-pre-assessments-for-an-apomorphine-response-test/2025-08-13T15:01:09+02:00https://parkinson.everpharma.com/apomorphine-response-test-via-quick-titration/2025-08-13T15:00:48+02:00https://parkinson.everpharma.com/skin-care-management-in-apomorphine-therapy/2026-07-31T10:20:52+02:00https://parkinson.everpharma.com/desjardins-et-al-apomorphine-monotherapy-for-parkinsons-disease-a-neglected-option/2024-02-21T14:51:30+01:00https://parkinson.everpharma.com/are-parkinsons-disease-patients-referred-too-late-for-device-aidedtherapies-and-how-can-better-informed-and-earlier-referrals-be-encouraged/2025-03-17T12:59:44+01:00https://parkinson.everpharma.com/continuous-subcutaneous-apomorphine-infusion-in-the-early-phase-ofadvanced-parkinsons-disease-a-prospective-study-of-22-patients/2024-02-21T14:50:11+01:00https://parkinson.everpharma.com/practical-use-of-apomorphine-infusion-in-parkinsons-disease-lessons-from-the-toledo-study-and-clinical-experience/2023-11-29T11:08:12+01:00https://parkinson.everpharma.com/drugs-to-the-rescue-comparison-of-on-demand-therapies-for-off-symptoms-in-parkinsons-disease/2024-02-21T14:47:17+01:00https://parkinson.everpharma.com/pharmacological-insights-into-the-use-of-apomorphinein-parkinsons-disease-clinical-relevance/2024-02-21T14:52:55+01:00https://parkinson.everpharma.com/genetics-in-parkinsons-disease/2025-08-14T12:50:33+02:00https://parkinson.everpharma.com/the-akinetic-crisis-in-parkinsons-disease/2025-08-14T12:50:51+02:00https://parkinson.everpharma.com/apomorphine-infusion-therapy-best-practices/2024-06-10T13:23:37+02:00https://parkinson.everpharma.com/information-for-stays-in-medical-facilities-as-part-of-apomorphine-therapy/2024-08-22T09:50:12+02:00https://parkinson.everpharma.com/on-the-road-with-the-apomorphine-pump/2025-08-13T14:29:27+02:00https://parkinson.everpharma.com/l-dopa-pharmacokinetic-limitations-in-pd-does-continuousdopaminergic-therapy-solve-the-problem/2024-12-11T11:08:43+01:00https://parkinson.everpharma.com/intermittent-on-demand-therapy-in-pd/2024-12-11T11:07:31+01:00https://parkinson.everpharma.com/patient-selection-suitable-patients-for-apomorphine-treatment/2024-12-11T11:06:44+01:00https://parkinson.everpharma.com/transfer-from-oral-pd-treatment-to-apomorphine-pump-infusions-in-colombia/2024-12-11T11:05:23+01:00https://parkinson.everpharma.com/how-data-triggers-to-ask-the-right-questions-in-pd-treatment/2024-12-11T11:02:42+01:00https://parkinson.everpharma.com/apomorphine-monotherapy/2024-12-11T10:59:59+01:00https://parkinson.everpharma.com/supporting-people-with-pd-the-carers-quality-of-life-and-burden/2024-12-11T10:59:13+01:00https://parkinson.everpharma.com/panel-discussion-symposium-2024/2024-12-10T17:07:48+01:00https://parkinson.everpharma.com/perioperative-medication-management-in-parkinsons-disease/2025-09-22T13:05:56+02:00https://parkinson.everpharma.com/the-mds-unified-parkinsons-disease-rating-scale-mds-updrs/2025-09-18T14:22:25+02:00https://parkinson.everpharma.com/definitions-of-technical-terms-in-parkinsons/2025-10-21T09:15:21+02:00https://parkinson.everpharma.com/the-importance-of-using-the-right-s-c-catheter-in-cont-apomorphine-pump-treatment/2025-09-16T19:16:48+02:00https://parkinson.everpharma.com/apomorphine-therapy-in-pd-patients-with-dementia/2025-09-22T13:04:41+02:00https://parkinson.everpharma.com/dopaminergic-challenge-tests-and-response-in-pd/2026-02-27T08:29:29+01:00https://parkinson.everpharma.com/how-to-decide-which-device-aided-therapy-to-use-in-advanced-pd/2026-02-17T10:40:38+01:00https://parkinson.everpharma.com/patient-selection-for-apomorphine-pump-infusions/2026-02-16T16:30:00+01:00https://parkinson.everpharma.com/considerations-to-rethink-apomorphine-pump-infusions/2026-02-16T16:29:23+01:00https://parkinson.everpharma.com/the-importance-of-asking-patients-the-right-questions-based-on-data/2026-02-27T08:30:44+01:00https://parkinson.everpharma.com/24-hours-use-of-apomorphine-infusions/2026-02-16T16:29:03+01:00https://parkinson.everpharma.com/the-carers-perspective-pd-nurse-education-for-parkinsons/2026-02-16T16:28:47+01:00https://parkinson.everpharma.com/panel-discussion-symposium-2026/2026-02-16T16:28:17+01:00